The consortium of universities that leads the National Center for Atmospheric Research (NCAR) is suing the Trump administration over the move to dismantle the nation's largest weather and climate ...

Transfer rules for high school senior athletes in South Carolina will remain the same for the 2026-27 school year. Athletic directors from around the state on Wednesday voted down an amendment that ...

Egypt-based Beltone Asset Management has secured initial FRA approval to launch “Fadda”, Egypt’s first silver investment fund with cumulative daily returns, introducing a new alternative asset class ...

KBRA assigns preliminary ratings to 71 classes of mortgage pass-through certificates from Sequoia Mortgage Trust 2026-INV2 (SEMT 2026-INV2). The transaction consists of 1,118 investment property ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Debra OConnell will become chairman of Disney Entertainment Television, while Disney's gaming business, led by Sean Shoptaw, will now report to Walden.

For “Titanic the Musical,” Arts Bonita Director Kody C. Jones has assembled a cast of 55 youth and adult actors. This is not ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Hollywood celebrated its biggest night of the year at the 2026 Oscars, and celebrities certainly brought their fashion A-game to the red carpet.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Scientists have developed a powerful new computational method that could accelerate the search for next-generation materials capable of turning sunlight into useful chemical energy. The work focuses ...

Structure Therapeutics said on Monday its pill helped patients lose up to 16.3% of their weight, strengthening its bid to challenge Eli Lilly ​and Novo Nordisk in the increasingly competitive race ...